https://orcid.org/0000-0002-6232-7450
References
- Engelhardt M., Ajayi S., Reinhardt H., Müller S.J., Dold S.M., Wäsch R. (2018) Pomalidomide. In: Martens U. (eds) Small Molecules in Hematology. Recent Results in Cancer Research, vol 212. Springer, Cham.
- POMALIDOMIDE | Drug | BNF content published by NICE [Internet]. [cited 2019]. Available from: https://bnf.nice.org.uk/drug/pomalidomide.html
- Lobbous M, Korf BR. Therapeutic development in neurofibromatosis. In: Francesco Signorelli, Raffaella Messina (Eds.)., Neurofibromatosis - current trends and future directions [Working Title]. London, United Kingdom: IntechOpen; 2019.
- Karajannis MA, Legault G, Hagiwara M, et al. Phase II trial of lapatinib in adult and pediatric patients with neurofibromatosis type 2 and progressive vestibular schwannomas NEURO-ONCO LO GY’. Neuro-Oncol 2012;14:1163–70.
- Plotkin SR, Stemmer-Rachamimov AO, Barker FG, et al. Hearing improvement after bevacizumab in patients with neurofibromatosis type 2. N Engl J Med 2009;361:358–67.
- Romani R, Pollock J. Spontaneous shrinkage of vestibular schwannoma. Surg Neurol Int 2016;7:59.
- von Eckardstein KL, et al. Spontaneous regression of vestibular schwannomas after resection of contralateral tumor in neurofibromatosis Type 2. JNS 2010;112:158–62.